Pidobenzone
CAS No. 138506-45-3
Pidobenzone( —— )
Catalog No. M37561 CAS No. 138506-45-3
Pidobenzone is a melanin synthesis inhibitor that blocks melanin deposition, eliminates melasma and brightens skin.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 344 | Get Quote |
|
| 5MG | 535 | Get Quote |
|
| 10MG | 753 | Get Quote |
|
| 25MG | 1132 | Get Quote |
|
| 50MG | 1536 | Get Quote |
|
| 100MG | 2025 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NamePidobenzone
-
NoteResearch use only, not for human use.
-
Brief DescriptionPidobenzone is a melanin synthesis inhibitor that blocks melanin deposition, eliminates melasma and brightens skin.
-
DescriptionPidobenzone is a melanin synthesis inhibitor that blocks melanin deposition, eliminates melasma and brightens skin.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number138506-45-3
-
Formula Weight221.21
-
Molecular FormulaC11H11NO4
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC(OC1=CC=C(O)C=C1)(=O)[C@@H]2CCC(=O)N2
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Lapathoside A
Lapathoside A and vanicoside B, inhibited the promotion stages on two-stage carcinogenesis induced by TPA.
-
Tremelimumab
Tremelimumab is a cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) blocking antibody.Tremelimumab is often used in combination with Durvalumab for the treatment of solid cancers such as hepatocellular carcinoma and lung cancer.
-
ACTB-1003
ACTB-1003 is an oral kinase inhibitor (IC50: 6/2/4 nM, for FGFR1/VEGFR2/Tie-2).
Cart
sales@molnova.com